ISSUE: Clinical relevance, budget impact and cost-effectiveness are important criteria in market access decisions. To what extent do these criteria incorporate and reflect the perspective of the patient? Do Patient Reported Outcomes (PRO) contribute to decision making? Currently, PRO are often poorly reported secondary outcomes in clinical trials and a wide range of different data exist of varying levels of quality. This makes synthesizing them difficult. Furthermore, is the often-used EQ-5D specific enough to capture crucial patient aspects as a basis for cost-utility analyses? So, the key issue is how to generate PRO data that can be appropriately incorporated when informing decision-making and contribute to improved outcomes for patients. OVERVIEW: Using PROs in healthcare decisions is a topic of considerable controversy. However, the basis for decisions can be improved by increased clarity on what kind of PRO data may impact market access decisions. The panel focuses on practical aspects of generating and synthesizing PROs, using diabetes care as an example, in the context of market access decision-making.